Porchet Hervé - Department of Pharmacology, University of Pretoria

基本信息

浏览量：20

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 24 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Author response for "A Safety and Pharmacodynamics Study of Temelimab, an anti‐HERV‐W‐Env Monoclonal Antibody, in Type 1 Diabetes Patients"

Francois Curtin,Bernard Champion,Peter Davoren,Sally Duke,Elif I Ekinci,Chris Gilfillan,Claire Morbey,Thomas Nathow, Trisha O'Moore‐Sullivan,David O'Neal,Adam Roberts,Stephen Stranks,Bronwyn Stuckey,Parind Vora,Sam Malpass,David Lloyd, Nicole Maëstracci‐Beard,Bénédicte Buffet,Gabrielle Kornmann,Corinne Bernard,Hervé Porchet,Richard Simpson

crossref（2020）

引用0浏览0引用

Neuroprotective effects of temelimab in relapsing-remitting MS patients extend to 96 weeks

H. P. Hartung,B. Cree,T. Derfuss,M. P. Sormani, B. Frederik,F. Curtin,H. -M. Schneble,R. Glanzman,H. Porchet,E. Lambert,K. Selmaj

MULTIPLE SCLEROSIS JOURNAL（2019）

引用1浏览0引用

A High-dose Pharmacokinetic Study of a New IgG4 Monoclonal Antibody Temelimab/GNbAC1 Antagonist of an Endogenous Retroviral Protein Pherv-W Env

Nerve Porchet,Virginie Vidal,Gabrielle Kornmann,Sam Malpass,Francois Curtin

CLINICAL THERAPEUTICSno. 9 (2019): 1737-1746

引用11浏览0WOS引用

Efficacy and Safety of Temelimab, an Antibody Antagonist of the Human Endogenous Retrovirus Type-W Env Protein, in Participants with Relapsing Remitting Multiple Sclerosis: A Double-Blind, Randomised, Placebo-Controlled Phase 2b Clinical Trial

Hans-Peter Hartung,Tobias Derfuss,Bruce Cree,Maria Pia Sormani,Krzysztof Selmaj,Jon Stutters,Ferran Prados,David MacManus,Hans-Martin Schneble,Hervé Porchet,Robert Glanzman,Estelle Lambert,Gordon Francis,Francois Curtin,Frederik Barkhof

Social Science Research Network (2019)

引用0浏览0引用

Week 24 Results: GNbAC1 in RRMS (GNC-003, CHANGE-MS; Clinical trial assessing the HERV-W Env antagonist GNbAC1 for Efficacy in MS)

Hans-Peter Hartung,Herve Porchet,Robert L. Glanzman,Estelle Lambert,Krzysztof W. Selmaj,Frederik Barkhof

MULTIPLE SCLEROSIS JOURNAL（2018）

引用0浏览0引用

A New Therapeutic Approach for Type 1 Diabetes: Rationale for GNbAC1, an Anti-Herv-w-env Monoclonal Antibody

Francois Curtin,Corinne Bernard,Sandrine Levet,Herve Perron,Herve Porchet,Julie Medina,Sam Malpass,David Lloyd,Richard Simpson

Diabetes, obesity & metabolism/Diabetes, obesity and metabolismno. 9 (2018): 2075-2084

引用35浏览0WOS引用

A Randomised Placebo-Controlled Study to Investigate GNbAC1 an Anti-Herv-w-env Monoclonal Antibody in Patients with Recent Onset of Type 1 Diabetes : Rationale and Design

François Curtin,Corinne Bernard,Hervé Porchet,Sandrine Levet, Jesús Weir Medina,Hervé Perron, Sharon Oates,David Lloyd, Richard Simpson

openalex（2018）

引用0浏览0引用

Week 48 results from a phase IIb trial of GNbAC1 in patients with relapsing remitting multiple sclerosis (CHANGE-MS; clinical trial assessing the HERV-W Env antagonist GNbAC1 for Efficacy in MS)

H. P. Hartung,K. Selmaj,R. Glanzman, F. Curtain,H. Porchet, H-M Schneble,E. Lambert, F. Barkhof

MULTIPLE SCLEROSIS JOURNAL（2018）

引用6浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn